The influence of SLC22A1 rs622342 and ABCC8 rs757110 genetic variants on the efficacy of metformin and glimepiride combination therapy in Egyptian patients with type 2 diabetes

References

• Upadhyay J, Polyzos SA, Perakakis N, et al. Pharmacotherapy of type 2 diabetes: An update. Metabolism. 2018;78:13–42.
   PubMed Web of Science ®Google Scholar
• Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2017;14:88–98.
   PubMed Web of Science ®Google Scholar
• Majeed A, El-Sayed AA, Khoja T, et al. Diabetes in the Middle-East and North Africa: An update. Diabetes Res Clin Pract. 2014;103:218–222.
   PubMed Web of Science ®Google Scholar
• Assaad Khalil SH, Megallaa MH, Rohoma KH, et al. Prevalence of type 2 diabetes mellitus in a sample of the adult population of Alexandria, Egypt. Diabetes Res Clin Pract. 2018;144:63–73.
   PubMed Web of Science ®Google Scholar
• Shelbaya S, Rakha S. Effectiveness and safety of vildagliptin and vildagliptin add-on to metformin in real-world settings in Egypt - results from the GUARD study. Curr Med Res Opin. 2017;33:797–801.
   PubMed Web of Science ®Google Scholar
• Cai X, Gao X, Yang W, et al. Efficacy and safety of initial combination therapy in Treatment-Naïve type 2 diabetes patients: a systematic review and Meta-analysis. Diabetes Ther. 2018;9:1995–2014.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. 8. Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes—2018. Diabetes Care [Internet]. 2018;41:S73 LP-S85.
   Google Scholar
• Cersosimo E, Johnson EL, Chovanes C, et al. Initiating therapy in patients newly diagnosed with type 2 diabetes: Combination therapy vs a stepwise approach. Diabetes Obes Metab. 2018;20:497–507.
   PubMed Web of Science ®Google Scholar
• Phung OJ, Sobieraj DM, Engel SS, et al. Early combination therapy for the treatment of type 2 diabetes mellitus: systematic review and meta-analysis. Diabetes Obes Metab. 2014;16:410–417.
   PubMed Web of Science ®Google Scholar
• Hassan MH, Abd-Allah GM. Effects of metformin plus gliclazide versus metformin plus glimepiride on cardiovascular risk factors in patients with type 2 diabetes mellitus. Pak J Pharm Sci. 2015;28:1723–1730.
   PubMed Web of Science ®Google Scholar
• Staiger H, Schaeffeler E, Schwab M, et al. Pharmacogenetics: Implications for modern type 2 diabetes therapy. Rev Diabet Stud. 2015;12:363–376.
   PubMedGoogle Scholar
• Ordelheide A, Hrabě de Angelis M, Häring H-U, et al. Pharmacogenetics of oral antidiabetic therapy. Pharmacogenomics. 2018;19:577–587.
   PubMed Web of Science ®Google Scholar
• Sundelin EIO, Gormsen LC, Jensen JB, et al. Genetic polymorphisms in organic cation transporter 1 attenuates hepatic metformin exposure in humans. Clin Pharmacol Ther. 2017;102:841–848.
   PubMed Web of Science ®Google Scholar
• Sanchez-Ibarra HE, Reyes-Cortes LM, Jiang X-L, et al. Genotypic and phenotypic factors influencing drug response in mexican patients with Type 2 diabetes mellitus. Front Pharmacol. 2018;9:320.
   PubMed Web of Science ®Google Scholar
• Dujic T, Zhou K, Yee SW, et al. Variants in pharmacokinetic transporters and glycemic response to metformin: a metgen Meta-Analysis. Clin Pharmacol Ther. 2017;101:763–772.
   PubMed Web of Science ®Google Scholar
• Pawlyk AC, Giacomini KM, McKeon C, et al. Metformin pharmacogenomics: current status and future directions. Diabetes. 2014;63:2590–2599.
   PubMed Web of Science ®Google Scholar
• Florez JC. The pharmacogenetics of metformin. Diabetologia. 2017;60:1648–1655.
   PubMed Web of Science ®Google Scholar
• Umamaheswaran G, Praveen RG, Damodaran SE, et al. Influence of SLC22A1 rs622342 genetic polymorphism on metformin response in South Indian type 2 diabetes mellitus patients. Clin Exp Med. 2015;15:511–517.
   PubMed Web of Science ®Google Scholar
• Becker ML, Visser LE, van Schaik RHN, et al. Genetic variation in the organic cation transporter 1 is associated with metformin response in patients with diabetes mellitus. Pharmacogenomics J. 2009;9:242–247.
   PubMed Web of Science ®Google Scholar
• rs622342 RefSNP Report - dbSNP - NCBI [Internet]. [cited 2019 Apr 20]. Available from: https://www.ncbi.nlm.nih.gov/snp/rs622342#publications.
   Google Scholar
• Becker ML, Visser LE, van Schaik RHN, et al. OCT1 polymorphism is associated with response and survival time in anti-Parkinsonian drug users. Neurogenetics. 2011;12:79–82.
   PubMed Web of Science ®Google Scholar
• Klen J, Dolžan V, Janež A. CYP2C9, KCNJ11 and ABCC8 polymorphisms and the response to sulphonylurea treatment in type 2 diabetes patients. Eur J Clin Pharmacol. 2014;70:421–428.
   PubMed Web of Science ®Google Scholar
• Ghanem AI, Rushdy S, Mokhtar M. Association between KCNJ11 & ABCC8 Genetic Polymorphism and Type 2 Diabetes in Egyptian Patients. Med J Cairo Univ. 2016;84:1501–1510.
   Google Scholar
• Cho H, Lee S, Kim Y-G, et al. Effect of genetic polymorphisms on the pharmacokinetics and efficacy of glimepiride in a Korean population. Clin Chim Acta. 2011;412:1831–1834.
   PubMed Web of Science ®Google Scholar
• van Leeuwen N, Swen JJ, Guchelaar H-J, et al. The role of pharmacogenetics in drug disposition and response of oral glucose-lowering drugs. Clin Pharmacokinet. 2013;52:833–854.
   PubMed Web of Science ®Google Scholar
• rs757110 RefSNP Report - dbSNP - NCBI [Internet]. [cited 2019 Apr 20]. Available from: https://www.ncbi.nlm.nih.gov/snp/rs757110.
   Google Scholar
• Sato R, Watanabe H, Genma R, et al. ABCC8 polymorphism (Ser1369Ala): influence on severe hypoglycemia due to sulfonylureas. Pharmacogenomics. 2010;11:1743–1750.
   PubMed Web of Science ®Google Scholar
• Knapp S, Zakaria Z, Hashem M, et al. Influence of IFNL3.rs12979860 and IFNL4.ss469415590 polymorphism on clearance of hepatitis C virus infection among Egyptians. Hepatol Int. 2015;9:251–257.
   PubMed Web of Science ®Google Scholar
• Khalil B, Shahin M, Solayman M, et al. Genetic and nongenetic factors affecting clopidogrel response in the Egyptian Population. Clin Transl Sci. 2016;9:23–28.
   PubMed Web of Science ®Google Scholar
• Shahin MHA, Khalifa SI, Gong Y, et al. Genetic and nongenetic factors associated with warfarin dose requirements in Egyptian patients. Pharmacogenet Genomics. 2011;21:130–135.
   PubMed Web of Science ®Google Scholar
• Lipscombe L, Booth G, Butalia S, et al. Diabetes Canada 2018 clinical practice guidelines for the prevention and management of diabetes in canada: pharmacologic glycemic management of Type 2 diabetes in adults. Can J Diabetes. 2018;42:S88–S103.
   PubMed Web of Science ®Google Scholar
• Sherifali D, Nerenberg K, Pullenayegum E, et al. The effect of oral antidiabetic agents on A1C levels: a systematic review and meta-analysis. Diabetes Care. 2010;33:1859–1864.
   PubMed Web of Science ®Google Scholar
• Dujic T, Zhou K, Donnelly LA, et al. Association of organic cation transporter 1 with intolerance to metformin in type 2 diabetes: A GoDARTS study. Diabetes. 2015;64:1786–1793.
   PubMed Web of Science ®Google Scholar
• Ahlin G, Chen L, Lazorova L, et al. Genotype-dependent effects of inhibitors of the organic cation transporter, OCT1: predictions of metformin interactions. Pharmacogenomics J. 2011;11:400–411.
   PubMed Web of Science ®Google Scholar
• eAG/A1C Conversion Calculator | American Diabetes Association [Internet]. [cited 2018 Sep 20]. Available from: https://professional.diabetes.org/diapro/glucose_calc.
   Google Scholar
• American Diabetes Association. 6. Glycemic targets: Standards of Medical Care in Diabetes—2018. Diabetes Care. 2018;41:S55–S64.
   Google Scholar
• Ren Q, Xiao D, Han X, et al. Genetic and clinical predictive factors of sulfonylurea failure in patients with Type 2 diabetes. Diabetes Technol Ther. 2016;18:586–593.
   PubMed Web of Science ®Google Scholar
• Qaseem A, Wilt TJ, Kansagara D, et al. Hemoglobin A1c targets for glycemic control with pharmacologic therapy for nonpregnant adults with type 2 diabetes mellitus: a guidance statement update from the American College of Physicians. Ann Intern Med. 2018;168:569–576.
   PubMed Web of Science ®Google Scholar
• Kim HY, Lee SY, Suh S, et al. The relationship between estimated average glucose and fasting plasma glucose. Clin Chem Lab Med. 2013;51:2195–2200.
   PubMed Web of Science ®Google Scholar
• Bozkaya G, Ozgu E, Karaca B. The association between estimated average glucose levels and fasting plasma glucose levels. Clinics. 2010;65:1077–1080.
   PubMed Web of Science ®Google Scholar
• Polonsky WH, Henry RR. Poor medication adherence in type 2 diabetes: Recognizing the scope of the problem and its key contributors. PPA. 2016;10:1299–1306.
   Google Scholar
• Pattnaik S, Ausvi S, Salgar A, et al. Treatment compliance among previously diagnosed type 2 diabetics in a rural area in Southern India. J Family Med Prim Care. 2019;8:919.
   PubMedGoogle Scholar
• Shams MEE, Barakat E. Measuring the rate of therapeutic adherence among outpatients with T2DM in Egypt. Saudi Pharm J. 2010;18:225.
   PubMedGoogle Scholar
• Zamek-Gliszczynski MJ, Giacomini KM, Zhang L. Emerging clinical importance of hepatic organic cation transporter 1 (OCT1) in drug pharmacokinetics, dynamics, pharmacogenetic variability, and drug interactions. Clin Pharmacol Ther. 2017;0:1–3.
   Google Scholar
• Christensen MMH, Højlund K, Hother-Nielsen O, et al. Steady-state pharmacokinetics of metformin is independent of the OCT1 genotype in healthy volunteers. Eur J Clin Pharmacol. 2015;71:691–697.
   PubMed Web of Science ®Google Scholar
• Becker ML, Visser LE, van Schaik RHN, et al. Interaction between polymorphisms in the OCT1 and MATE1 transporter and metformin response. Pharmacogenet Genomics. 2010;20:38–44.
   PubMed Web of Science ®Google Scholar
• Tkáč I, Klimčáková L, Javorský M, et al. Pharmacogenomic association between a variant in SLC47A1 gene and therapeutic response to metformin in type 2 diabetes. Diabetes Obes Metab. 2013;15:189–191.
   PubMed Web of Science ®Google Scholar
• Umamaheswaran G, Praveen RG, Arunkumar AS, et al. Genetic analysis of OCT1 gene polymorphisms in an Indian population. Indian J Hum Genet. 2011;17:164–168.
   PubMedGoogle Scholar
• Du Plessis M, Pearce B, Jacobs C, et al. Genetic polymorphisms of the organic cation transporter 1 gene (SLC22A1) within the Cape Admixed population of South Africa. Mol Biol Rep. 2015;42:665–672.
   PubMed Web of Science ®Google Scholar
• Jablonski KA, McAteer JB, de Bakker PIW, et al. Common variants in 40 genes assessed for diabetes incidence and response to metformin and lifestyle intervention in the diabetes prevention program. Diabetes. 2010;59:2672–2681.
   PubMed Web of Science ®Google Scholar
• Fatehi M, Carter CRJ, Youssef N, et al. Molecular determinants of ATP-sensitive potassium channel MgATPase activity: diabetes risk variants and diazoxide sensitivity. Biosci Rep. 2015;35:1–11.
   PubMed Web of Science ®Google Scholar
• Rasheed MA, Kantoush N, Abd El-Ghaffar N, et al. Expression of JAZF1, ABCC8, KCNJ11and Notch2 genes and vitamin D receptor polymorphisms in type 2 diabetes, and their association with microvascular complications. Ther Adv Endocrinol Metab. 2017;8:97–108.
   PubMed Web of Science ®Google Scholar
• Holstein JD, Kovacs P, Patzer O, et al. The Ser1369Ala variant of ABCC8 and the risk for severe sulfonylurea-induced hypoglycemia in German patients with Type 2 diabetes. Pharmacogenomics. 2012;13:5–7.
   PubMed Web of Science ®Google Scholar
• Hamming KSC, Soliman D, Matemisz LC, et al. Coexpression of the type 2 diabetes susceptibility gene variants KCNJ11 E23K and ABCC8 S1369A alter the ATP and sulfonylurea sensitivities of the ATP-sensitive K(+) channel. Diabetes. 2009;58:2419–2424.
   PubMed Web of Science ®Google Scholar
• Lang VY, Fatehi M, Light PE. Pharmacogenomic analysis of ATP-sensitive potassium channels coexpressing the common type 2 diabetes risk variants E23K and S1369A. Pharmacogenet Genomics. 2012;22:206–214.
   PubMed Web of Science ®Google Scholar
• Feng Y, Mao G, Ren X, et al. Ser 1369Ala variant in sulfonylurea receptor gene ABCC8 Is associated with antidiabetic efficacy of gliclazide in Chinese Type 2 diabetic patients. Diabetes Care. 2008;31:1939–1944.
   PubMed Web of Science ®Google Scholar